Penlan Pharmaceuticals logo
Request a formulary pack or sales call

References

  1. Barcelo, P., Wuhl, O., Servitge, E., Rousaud, A., & Pak, C. Y. C. (1993). Randomized Double-Blind Study of Potassium Citrate in Idiopathic Hypocitraturic Calcium Nephrolithiasis. Journal of Urology, 150(6), 1761–1764. https://doi.org/10.1016/S0022-5347(17)35888-3
  2. Ettinger, B., Pak, C. Y. C., Citron, J. T., Thomas, C., Adams-Huet, B., & Vangessel, A. (1997). Potassium-Magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Journal of Urology, 158(6), 2069–2073. https://doi.org/10.1016/S0022-5347(01)68155-2
  3. Soygür, T., Akbay, A., & Küpeli, S. (2002). Effect of Potassium Citrate Therapy on Stone Recurrence and Residual Fragments after Shockwave Lithotripsy in Lower Caliceal Calcium Oxalate Urolithiasis: A Randomized Controlled Trial. Journal of Endourology, 16(3), 149–152. https://doi.org/10.1089/089277902753716098
  4. Phillips, R., Hanchanale, V. S., Myatt, A., Somani, B., Nabi, G., & Biyani, C. S. (2015). Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database of Systematic Reviews, 2015(10). https://doi.org/10.1002/14651858.CD010057.pub2
  5. NICE Renal and ureteric stones: assessment and management (NG118), January 2019
  6. Commentary on the NICE Guideline on Renal and ureteric stones: assessment and management (2021) J Sawyer et al.
  7. Gloucester Hospitals, Dissolving Kidney Stones, (GHPI1838_04_24) April 2024
  8. https://www.kidney.org/kidney-topics/kidney-stones
  9. Wilcox CR, Whitehurst LA, Cook P, Somani BK. Kidney stone disease: an update on its management in primary care. The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 2020 Apr;70(693):205-206. DOI: 10.3399/bjgp20x709277. PMID: 32217603; PMCID: PMC7098514.
  10. Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years. BJU Int. 2020 Apr;125(4):586-594. doi: 10.1111/bju.14991. Epub 2020 Jan 24. PMID: 31916369.
  11. Dorset Formularyhttps://www.dorsetformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=7&SubSectionRef=07.04.03&SubSectionID=B100#2009
  12. https://www.ncl-jointformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=7&SubSectionRef=7.04.03&SubSectionID=B100
  13. Data on File 100036_001 v1.0 January 2026.
  14. Patient Information Leaflet and Summary of Product Characteristics https://www.medicines.org.uk/emc/product/101807/smpc
  15. Salem SM, Sultan MF, Badawy A. Oral dissolution therapy for renal radiolucent stones, outcome, and factors affecting response: A prospective study. Urol Ann. 2019;11(4):369-373.
  16. Petritsch PH. Uric acid calculi: results of conservative treatment. Urology. 1977 Dec;10(6):536
  17. Elsawy AA, Elshal AM, El-Nahas AR, Elbaset MA, Farag H, Shokeir AA. Can We Predict the Outcome of Oral Dissolution Therapy for Radiolucent Renal Calculi? A Prospective Study. J Urol. 2019;201(2):350-357.